# Wěi Li

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/wei-li-9/

## Facts

| Field | Value |
| --- | --- |
| Citations | 74,732 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 109 |
| i10-index | 1,048 |
| Last Known Institution | Beijing Tongren Hospital |
| OpenAlex ID | https://openalex.org/A5100318325 |
| ORCID iD | https://orcid.org/0000-0002-9522-4474 |
| Works | 2,221 |

## Researcher papers

- [Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer](https://scholariq.org/papers/trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer/)
- [Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial](https://scholariq.org/papers/afatinib-versus-cisplatin-plus-gemcitabine-for-first-line-treatment-of-asian/)
- [Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study](https://scholariq.org/papers/gefitinib-versus-vinorelbine-plus-cisplatin-as-adjuvant-treatment-for-stage-ii/)
- [Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis](https://scholariq.org/papers/integrative-analysis-of-hif-binding-and-transactivation-reveals-its-role-in/)
- [Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial](https://scholariq.org/papers/pyrotinib-plus-capecitabine-versus-lapatinib-plus-capecitabine-for-the-treatment/)
- [Gut epithelial TSC1/mTOR controls RIPK3-dependent necroptosis in intestinal inflammation and cancer](https://scholariq.org/papers/gut-epithelial-tsc1-mtor-controls-ripk3-dependent-necroptosis-in-intestinal/)
- [Drug-Coated Balloon Versus Drug-Eluting Stent for Small-Vessel Disease](https://scholariq.org/papers/drug-coated-balloon-versus-drug-eluting-stent-for-small-vessel-disease/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Synthesis and biological activity](https://scholariq.org/topics/synthesis-and-biological-activity/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Click Chemistry and Applications](https://scholariq.org/topics/click-chemistry-and-applications/)

## Researcher university

- [Beijing Tongren Hospital](https://scholariq.org/institutions/beijing-tongren-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.